SENSCIS trial compared 1 yr of nintedanib (NIN) vs placebo in 576 SSc-ILD pts. NIN was more effective (less FVC decline) in 1) α-topoisomerase Ab neg (57.2 vs 30 ATA+), 2) mRSS ≥18 (88.7 vs 26 mRSS<18), & 3) diffuse (57 vs local 25) SSc pts https://t.co/cLuTBDeJD6